VEGF-B Antibody - 167/186

• Reactivity: Hu
• Applications: WB
• Clonality: Polyclonal
• Host: Goat
• Conjugate: Unconjugated
• Concentration: LYOPH

VEGF-B Antibody - 167/186 Summary

• Immunogen: E. coli-derived recombinant human VEGF-B₁₈₆
• Specificity: Detects human VEGF-B₁₆₇ and human VEGF-B₁₈₆ in direct ELISAs and Western blots. In direct ELISAs, less than 1% cross-reactivity with recombinant mouse (rm) VEGF-B_186, rmVEGF-B_167, rmVEGF-B_206, recombinant human (rh) VEGF-A, rhVEGF-C, and rhVEGF-D is observed.
• Source: N/A
• Isotype: IgG
• Clonality: Polyclonal
• Host: Goat
• Gene: VEGFB
• Purity: Immunogen affinity purified
• Purity Statement: Antigen Affinity-purified

Applications/Dilutions

• Dilutions:
  • Western Blot 0.1 ug/mL

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Preservative: No Preservative
• Concentration: LYOPH
• Purity: Immunogen affinity purified
• Reconstitution Instructions: Reconstitute at 0.2 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for VEGF-B Antibody - 167/186

• vascular endothelial growth factor B
• VEGFB
• VEGF-B
• VEGF-related factor
• VRFVEGFL

Background

Vascular endothelial growth factor B (VEGF-B), also known as vascular endothelial growth factor-related factor (VRF), is a member of the VEGF family of growth factors that share structural and functional similarity (1, 2). Five mammalian members, including VEGF-A, -B, -C, -D and PlGF, have been identified. VEGF family members are disulfide-linked dimeric proteins that are important regulators of physiological and pathological vasculogenesis, angiogenesis and lymphangiogenesis. VEGF-B is expressed in most tissues, especially in heart, skeletal muscle and pancreas. In many tissues, VEGF-B is co-expressed and can heterodimerize with VEGF (3). By alternative splicing, two isoforms of mature VEGF-B containing 167 or 186 amino acid (aa) residues exist (3, 4). The two VEGF-B isoforms have identical amino-terminal cysteine-knot VEGF homology domains but the carboxyl end of VEGF-B₁₆₇ differs from that of VEGF-B₁₈₆ by the presence of a highly basic cysteine-rich heparin binding domain. Whereas VEGF-B₁₈₆ is a secreted diffusible protein, VEGF-B₁₆₇ is sequestered into the cell matrix after secretion. Both VEGF-B isoforms bind VEGF receptor 1 (VEGF R1), but not VEGF R2 or VEGF R3 (5). On endothelial cells, ligation of VEGF R1 by VEGF-B has been shown to regulate the expression and activity of urokinase type plasminogen activator and plasminogen activator inhibitor 1. VEGF-B₁₆₇ and a proteolytically processed form of VEGF-B₁₈₆ (VEGF-B₁₂₇) also bind neuropilin-1 (NP-1), a type I transmembrane receptor for semaphorins/collapsins, ligands involved in neuron guidance (6). Besides VEGF-B, NP-1 has been shown to bind PLGF-2, VEGF₁₆₅ and VEGF R1 (6, 7). The many interactions of NP-1 with VEGF ligands and receptor suggests that NP-1 may function as a regulator of angiogenesis (7).

1. Li, X. and U. Eriksson (2001) Int. J. Biochem Cell Biol. 33:421.
2. Olofsson, B. et al. (1999) Curr. Opin. Biotechnol. 10:528.
3. Olofsson, B. et al. (1996) Proc. Nat. Acad. Sci. USA 93:2576.
4. Grimmond, S. et al. (1996) Benome Res. 6:124.
5. Olofsson, B. et al. (1998) Proc. Nat. Acad. Sci. USA 95:11709.
6. Makinen, T. et al. (1999) J. Biol. Chem. 274:21217.
7. Fuh, G. et al. (2000) J. Biol. Chem. 275:26690.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for VEGF-B Antibody (AF751)(5)

Publications using AF751

• Fan F, Samuel S, Gaur P Chronic exposure of colorectal cancer cells to bevacizumab promotes compensatory pathways that mediate tumour cell migration. Br. J. Cancer, 2011;104(8):1270-7. 2011 [PMID: 21407219] (Western Blot, Human)
• Fan F, Gray MJ, Dallas NA, Yang AD, Van Buren G, Camp ER, Ellis LM Effect of chemotherapeutic stress on induction of vascular endothelial growth factor family members and receptors in human colorectal cancer cells. Mol. Cancer Ther., 2008;7(9):3064-70. 2008 [PMID: 18790786] (Western Blot, Human)
• Tham E, Wang J, Piehl F, Weber G Upregulation of VEGF-A without angiogenesis in a mouse model of dilated cardiomyopathy caused by mitochondrial dysfunction. J. Histochem. Cytochem., 2002;50(7):935-44. 2002 [PMID: 12070272] (Western Blot, Mouse)
• Zhou Y, 2019, McMaster M, Woo K, Janatpour M, Perry J, Karpanen T, Alitalo K, Damsky C, Fisher SJ Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are dysregulated in severe preeclampsia and hemolysis, elevated liver enzymes, and low platelets syndrome. , 2002;160(4):1405-23. 2002 [PMID: 11943725] (IHC, Human)
• Okruzhnov Y, Nicholas J Human herpesvirus 8 (HHV-8)-encoded cytokines induce expression of and autocrine signaling by vascular endothelial growth factor (VEGF) in HHV-8-infected primary-effusion lymphoma cell lines and mediate VEGF-independent antiapoptotic effects. J. Virol., 2001;75(22):10933-40. 2001 [PMID: 11602733] (Western Blot, Human)

Bioinformatics

• Gene Symbol: VEGFB